Mammalian Genome

, Volume 15, Issue 7, pp 537–543

Response of TNF-hyporesponsive SPRET/Ei mice in models of inflammatory disorders

  • Jan Staelens
  • Leen Puimège
  • Tina Mahieu
  • Gwenda Pynaert
  • Tino Hochepied
  • Annelies Vandenabeele
  • Johan Grooten
  • Dimitris Kontoyiannis
  • Frans Van Roy
  • George Kollias
  • Claude Libert
Article
  • 35 Downloads

Abstract

Most inflammatory disorders are becoming more prevalent, especially in Western countries. The proinflammatory cytokine tumor necrosis factor-α (TNF) plays a prominent role in many of these inflammatory disorders. We have previously shown that SPRET/Ei mice exhibit an extreme and dominant resistance to high doses of TNF. In this report, we investigate the response of heterozygous (C57BL/6xSPRET/Ei)F1 mice in different models of inflammatory diseases. Compared with C57BL/6 mice, (B × S)F1 mice are protected against TNF-induced arthritis and are partially protected against allergic asthma in an ovalbumin-induced model. However, these mice display complete susceptibility to TNF-induced inflammatory bowel disease. These results indicate that the SPRET/Ei genome harbors potent dominant antiinflammatory genes that might be relevant for the treatment of certain chronic inflammatory diseases. It is very well possible that different genes are implicated in the different models.

Abbreviations:

OVA

chicken ovalbumin

PBS

phosphate buffered saline

TNF

tumor necrosis factor alpha

RA

rheumatoid arthritis

IBD

inflammatory bowel disease

TD

tissue destruction

BAL

brochoalveolar lavage

BALF

BAL fluid

B

C57BL/6

S

SPRET/Ei

References

  1. Anonymous2000AsthmaNat Biotechnol18IT10-1Google Scholar
  2. Broide, DH, Stachnick, G, Castaneda, D, Nayar, J, Sriramarao, P 2001Inhibition of eosinophilic inflammation in allergen-challenged TNF receptor p55/p75-and TNF receptor p55-deficient miceAm J Respir Cell Mol Biol24304311PubMedGoogle Scholar
  3. Kollias, G, Douni, E, Kassiotis, G, Kontoyiannis, D 1999aThe function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel diseaseAnn Rheum Dis58132139Google Scholar
  4. Kollias, G, Douni, E, Kassiotis, G, Kontoyiannis, D 1999bOn the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel diseaseImmunol Rev169175194Google Scholar
  5. Kontoyiannis, D, Pasparakis, M, Pizarro, TT, Cominelli, F, Kollias, G 1999Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologiesImmunity10387398CrossRefPubMedGoogle Scholar
  6. Kontoyiannis, D, Boulougouris, G, Manoloukos, M, Armaka, M, Apostolaki, M,  et al. 2002Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn’s-like inflammatory bowel diseaseJ Exp Med19615631574CrossRefPubMedGoogle Scholar
  7. Korsgren, M, Erjefalt, JS, Korsgren, O, Sundler, F, Persson, CG 1997Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient miceJ Exp Med185885892CrossRefPubMedGoogle Scholar
  8. Kroesen, S, Widmer, AF, Tyndall, A, Hasler, P 2003Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapyRheumatology42617621Google Scholar
  9. Lipsky, PE, Heijde, DM, St. Clair, EW, Furst, DE, Breedveld, FC,  et al. 2000Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study GroupN Engl J Med34315941602CrossRefPubMedGoogle Scholar
  10. Maini, R, St. Clair, EW, Breedveld, F, Furst, D, Kalden, J,  et al. 1999Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study GroupLancet35419321939CrossRefPubMedGoogle Scholar
  11. Mannel, DN, Echtenacher, B 2000TNF in the inflammatory responseChem Immunol74141161PubMedGoogle Scholar
  12. Moreland, LW, Schiff, MH, Baumgartner, SW, Tindall, EA, Fleischmann, RM,  et al. 1999Etanercept therapy in rheumatoid arthritis. A randomized, controlled trialAnn Intern Med130478486PubMedGoogle Scholar
  13. O’Neil, D, Steidler, L 2003Cytokines, chemokines and growth factors in the pathogenesis and treatment of inflammatory bowel diseaseAdv Exp Med Biol520252285PubMedGoogle Scholar
  14. Persidis, A 1999Arthritis drug discoveryNat Biotechnol17726728CrossRefPubMedGoogle Scholar
  15. Rothe, J, Lesslauer, W, Lotscher, H, Lang, Y, Koebel, P,  et al. 1993Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenesNature364798802CrossRefPubMedGoogle Scholar
  16. Rudmann, DG, Moore, MW, Tepper, JS, Aldrich, MC, Pfeiffer, JW,  et al. 2000Modulation of allergic inflammation in mice deficient in TNF receptorsAm J Physiol Lung Cell Mol Physiol279L10471057PubMedGoogle Scholar
  17. Sandbrn, WJ, Hanauer, SB 1999Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safetyInflamm Bowel Dis5119133PubMedGoogle Scholar
  18. Staelens, J, Wielockx, B, Puimege, L, Roy, F, Guenet, JL,  et al. 2002Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapyProc Natl Acad Sci USA9993409345CrossRefPubMedGoogle Scholar
  19. Thomas, PS 2001Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthmaImmunol Cell Biol79132140CrossRefPubMedGoogle Scholar
  20. Umetsu, DT, McIntire, JJ, Akbari, O, Macaubas, C, DeKruyff, RH 2002Asthma: an epidemic of dysregulated immunityNat Immunol3715720CrossRefPubMedGoogle Scholar
  21. Vassalli, P 1992The pathophysiology of tumor necrosis factorsAnnu Rev Immunol10411452CrossRefPubMedGoogle Scholar
  22. Weinblatt, ME, Kremer, JM, Bankhurst, AD, Bulpitt, KJ, Fleischmann, RM,  et al. 1999A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateN Engl J Med340253259CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Jan Staelens
    • 1
  • Leen Puimège
    • 1
  • Tina Mahieu
    • 1
  • Gwenda Pynaert
    • 2
  • Tino Hochepied
    • 1
  • Annelies Vandenabeele
    • 1
  • Johan Grooten
    • 3
  • Dimitris Kontoyiannis
    • 3
  • Frans Van Roy
    • 1
  • George Kollias
    • 3
  • Claude Libert
    • 1
  1. 1.Unit for Molecular Genetics in the Mouse, Department of Molecular Biomedical ResearchGhent University-Flanders Interuniversity Institute for BiotechnologyZwijnaardeBelgium
  2. 2.Unit for Molecular Immunology, Department of Molecular Biomedical ResearchGhent University-Flanders Interuniversity Institute for BiotechnologyZwijnaardeBelgium
  3. 3.Laboratory of Molecular GeneticsAlexander Fleming Biomedical Sciences Research InstituteVariGreece

Personalised recommendations